SLC5A2 and Hyperinsulinemia: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have a unique mode of action to lower plasma glucose levels in an insulin-independent manner via an increase in urinary glucose excretion, which in turn can mitigate glucotoxicity and hyperinsulinemia [8].